Celgene has become Forma Therapeutics’ latest partner with a deal to discover, develop and commercialise drug candidates that regulate targets involved in protein homeostasis. Celgene will have the option to obtain the ex-US rights to multiple drug candidates after evaluating selected targets and lead assets in protein homeostasis pathways during the preclinical phase of the collaboration. In an evolution of deal structure for the company, Forma will be responsible for advancing compounds through the completion of Phase I in collaboration with its partner TGen Drug Development.